Cytokeratin 20: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
*Pancreatic adenocarcinoma. | *Pancreatic adenocarcinoma. | ||
*Ovarian mucinous carcinoma. | *Ovarian mucinous carcinoma. | ||
*Occasionally stomach. | *Occasionally stomach adenocarcinoma, cholangiocarcinoma. | ||
*[[Urothelial carcinoma]]. | *[[Urothelial carcinoma]]. | ||
*[[Esophageal adenocarcinoma]]. | *[[Esophageal adenocarcinoma]]. | ||
| Line 25: | Line 25: | ||
==See also== | ==See also== | ||
*[[Immunohistochemistry]]. | *[[Immunohistochemistry]]. | ||
*[[CK7]]. | |||
==References== | ==References== | ||
Latest revision as of 13:41, 5 January 2017
Cytokeratin 20, abbreviated CK20, is a commonly used immunostain. It is also known as keratin 20.
Positive
CK20 positive and CK7 negative
- Virtually all colorectal carcinomas.[1]
- Merkel cell carcinoma - perinuclear dot-like pattern.
- Eosinophilic, solid and cystic renal cell carcinoma - an evolving entity.
Partially CK20 positive
- Corticotrophic pituitary adenomas and Crooke-hyaline changes.[2]
CK20 positive and CK7 positive
- Pancreatic adenocarcinoma.
- Ovarian mucinous carcinoma.
- Occasionally stomach adenocarcinoma, cholangiocarcinoma.
- Urothelial carcinoma.
- Esophageal adenocarcinoma.
Images
-
UCC - CK20 - intermed. mag. (WC) -
UCC - CK20 - high mag. (WC)
See also
References
- ↑ Chu, P.; Wu, E.; Weiss, LM. (Sep 2000). "Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.". Mod Pathol 13 (9): 962-72. doi:10.1038/modpathol.3880175. PMID 11007036.
- ↑ Eschbacher, JM.; Coons, SW. (2006). "Cytokeratin CK20 is a sensitive marker for Crooke's cells and the early cytoskeletal changes associated with hypercortisolism within pituitary corticotrophs.". Endocr Pathol 17 (4): 365-76. PMID 17525485.